Equity ratings for Idera Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting July 16, 2019 and ending today October 14, 2019. Click here to learn more.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. The company was founded in 1989 and is based in Exton, Pennsylvania. Idera Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 36 people. more
Idera Pharmaceuticals (IDRA) is traded on BATS Exchange in USA. It is located in 505 Eagleview Blvd., Suite 212, Exton, PA 19341, United States and employs 36 people. Idera Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 84.51 M. Idera Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.84 M outstanding shares of which 826.22 K shares are currently shorted by private and institutional investors with about 4.23 trading days to cover.
IDERA PHARMACEUTI currently holds about 52.37 M in cash with (46.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Idera Pharmaceuticals Probability Of Bankruptcy
Based on normal probability distribution, the odds of Idera Pharmaceuticals to move above current price in 30 days from now is about 54.81 (This Idera Pharmaceuticals probability density function shows the probability of Idera Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .